Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$152M |
| 2 |
AT&T
T
|
+$119M |
| 3 |
Norfolk Southern
NSC
|
+$117M |
| 4 |
CSX Corp
CSX
|
+$115M |
| 5 |
Booking.com
BKNG
|
+$104M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$156M |
| 3 |
C.H. Robinson
CHRW
|
+$134M |
| 4 |
PARA
Paramount Global Class B
PARA
|
+$130M |
| 5 |
BCR
CR Bard Inc.
BCR
|
+$100M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 18.4% |
| 2 | Industrials | 9.75% |
| 3 | Financials | 7.9% |
| 4 | Consumer Staples | 7.89% |
| 5 | Healthcare | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
PUT
Acadia Pharmaceuticals
ACAD
$5.11B
| $280K | ﹤0.01% |
+10,000
| New | +$218K |
|
|
EFC
1027
Ellington Financial
EFC
$1.76B
| $280K | ﹤0.01% |
+16,096
| New | +$269K |
|
1028
Acco Brands
ACCO
$387M
| $276K | ﹤0.01% |
30,785
+10,890
| +55% | +$76.2K |
|
1029
eBay
EBAY
$47.7B
| $275K | ﹤0.01% |
11,530
+2,925
| +34% | +$71.2K |
|
|
TEN
1030
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $271K | ﹤0.01% |
+5,260
| New | +$231K |
|
1031
Avient
AVNT
$4.07B
| $270K | ﹤0.01% |
+8,910
| New | +$245K |
|
1032
ePlus
PLUS
$2.25B
| $269K | ﹤0.01% |
13,360
-3,840
| -22% | -$79.2K |
|
|
ADT
1033
DELISTED
ADT Corp
ADT
| $264K | ﹤0.01% |
+6,390
| New | +$224K |
|
|
NEWP
1034
DELISTED
NEWPORT CORP
NEWP
| $264K | ﹤0.01% |
11,480
-3,870
| -25% | -$70.7K |
|
|
LJPC
1035
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $264K | ﹤0.01% |
+12,630
| New | +$225K |
|
|
INN
1036
Summit Hotel Properties
INN
$662M
| $263K | ﹤0.01% |
+22,000
| New | +$234K |
|
1037
Omnicell
OMCL
$1.58B
| $263K | ﹤0.01% |
9,430
+2,190
| +30% | +$60.1K |
|
1038
SunCoke Energy
SXC
$816M
| $263K | ﹤0.01% |
+40,390
| New | +$172K |
|
1039
Autoliv
ALV
$9.02B
| $260K | ﹤0.01% |
3,041
-9,683
| -76% | -$766K |
|
|
MDCO
1040
DELISTED
Medicines Co
MDCO
| $260K | ﹤0.01% |
8,169
-155,885
| -95% | -$5.09M |
|
1041
OneMain Financial
OMF
$7.23B
| $259K | ﹤0.01% |
+9,430
| New | +$255K |
|
1042
Dover
DOV
$27.4B
| $258K | ﹤0.01% |
4,964
-14,744
| -75% | -$715K |
|
1043
Bio-Techne
TECH
$11.3B
| $255K | ﹤0.01% |
+10,784
| New | +$238K |
|
|
IDTI
1044
DELISTED
Integrated Device Technology I
IDTI
| $255K | ﹤0.01% |
12,468
-1,084,175
| -99% | -$22.8M |
|
|
SPR
1045
DELISTED
Spirit AeroSystems
SPR
| $253K | ﹤0.01% |
+5,580
| New | +$254K |
|
1046
Xylem
XYL
$26.7B
| $253K | ﹤0.01% |
6,185
-433,870
| -99% | -$16M |
|
|
KNL
1047
DELISTED
Knoll, Inc.
KNL
| $253K | ﹤0.01% |
+11,700
| New | +$220K |
|
1048
Central Garden & Pet Co
CENT
$2.77B
| $252K | ﹤0.01% |
+19,263
| New | +$218K |
|
1049
Methode Electronics
MEI
$498M
| $252K | ﹤0.01% |
+8,618
| New | +$234K |
|
1050
NRG Energy
NRG
$23.5B
| $252K | ﹤0.01% |
+19,390
| New | +$222K |
|
Similar funds
Dmitry Balyasny's Q1 2016 Portfolio in Review
As of Q1 2016, Dmitry Balyasny held 1,764 positions worth $16.8B, up 17% from $14.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Dmitry Balyasny deployed $2.2B of net new capital in Q1 2016, opening 564 new positions and adding to 341 existing holdings. Its largest new stake was Norfolk Southern: 1,546,641 shares worth $129M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $187M trimmed.
- Dmitry Balyasny's largest Q1 2016 buy was Norfolk Southern: 1,546,641 shares worth $129M.
- Dmitry Balyasny added most to Marathon Petroleum in Q1 2016, an estimated $152M increase.
- Dmitry Balyasny's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $187M.
- Dmitry Balyasny fully exited Union Pacific in Q1 2016, selling an estimated $79.7M.
- Dmitry Balyasny's ten largest holdings make up 12% of its $16.8B portfolio in Q1 2016.
- Dmitry Balyasny opened 564 new positions and closed 526 in Q1 2016.
- Dmitry Balyasny's portfolio value rose 17% quarter-over-quarter to $16.8B.
Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.